{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:30Z","timestamp":1791204630041,"version":"4.2.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T00:00:00Z","timestamp":1424822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40272-015-0120-x","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T20:40:26Z","timestamp":1424810426000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Guide to the Use of Anticoagulant Drugs in Children"],"prefix":"10.1007","volume":"17","author":[{"given":"Connie","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Raffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"issue":"4","key":"120_CR1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","volume":"124","author":"L Raffini","year":"2009","unstructured":"Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children\u2019s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001\u20138. doi: 10.1542\/peds.2009-0768 .","journal-title":"Pediatrics"},{"issue":"2 Suppl","key":"120_CR2","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","volume":"141","author":"P Monagle","year":"2012","unstructured":"Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S\u2013801S. doi: 10.1378\/chest.11-2308 .","journal-title":"Chest"},{"issue":"5","key":"120_CR3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.V83.5.1251.1251","volume":"83","author":"M Andrew","year":"1994","unstructured":"Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251\u20137.","journal-title":"Blood"},{"issue":"1","key":"120_CR4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","volume":"70","author":"M Andrew","year":"1987","unstructured":"Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70(1):165\u201372.","journal-title":"Blood"},{"issue":"6","key":"120_CR5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.thromres.2005.11.004","volume":"118","author":"V Ignjatovic","year":"2006","unstructured":"Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, et al. Age-related differences in heparin response. Thromb Res. 2006;118(6):741\u20135. doi: 10.1016\/j.thromres.2005.11.004 .","journal-title":"Thromb Res"},{"key":"120_CR6","unstructured":"In: The joint commission national patient safety goals. http:\/\/www.jointcommission.org\/standards_information\/jcfaqdetails.aspx?StandardsFaqId=183&ProgramId=47 . Accessed 16 Feb 2015."},{"issue":"11","key":"120_CR7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-013-0094-1","volume":"52","author":"DL Yee","year":"2013","unstructured":"Yee DL, O\u2019Brien SH, Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013;52(11):967\u201380. doi: 10.1007\/s40262-013-0094-1 .","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"120_CR8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1203\/00006450-198107000-00007","volume":"15","author":"MM McDonald","year":"1981","unstructured":"McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res. 1981;15(7):1015\u20138. doi: 10.1203\/00006450-198107000-00007 .","journal-title":"Pediatr Res"},{"issue":"1","key":"120_CR9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/00006450-199401000-00016","volume":"35","author":"M Andrew","year":"1994","unstructured":"Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35(1):78\u201383. doi: 10.1203\/00006450-199401000-00016 .","journal-title":"Pediatr Res"},{"issue":"3","key":"120_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2165\/00003088-198005030-00002","volume":"5","author":"JW Estes","year":"1980","unstructured":"Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980;5(3):204\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"120_CR11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","volume":"287","author":"D Basu","year":"1972","unstructured":"Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287(7):324\u20137. doi: 10.1056\/NEJM197208172870703 .","journal-title":"N Engl J Med"},{"issue":"3","key":"120_CR12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1538-7836.2012.04624.x","volume":"10","author":"T Schechter","year":"2012","unstructured":"Schechter T, Finkelstein Y, Ali M, Kahr WH, Williams S, Chan AK, et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost. 2012;10(3):368\u201374. doi: 10.1111\/j.1538-7836.2012.04624.x .","journal-title":"J Thromb Haemost"},{"issue":"6","key":"120_CR13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","volume":"32","author":"JW Vandiver","year":"2012","unstructured":"Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546\u201358. doi: 10.1002\/j.1875-9114.2011.01049.x .","journal-title":"Pharmacotherapy"},{"issue":"547","key":"120_CR14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1259\/0007-1285-46-547-548","volume":"46","author":"JP Sackler","year":"1973","unstructured":"Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol. 1973;46(547):548\u201350.","journal-title":"Br J Radiol"},{"issue":"8827","key":"120_CR15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/0140-6736(92)93118-7","volume":"340","author":"MS Murphy","year":"1992","unstructured":"Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet. 1992;340(8827):1098.","journal-title":"Lancet"},{"issue":"20","key":"120_CR16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","volume":"332","author":"TE Warkentin","year":"1995","unstructured":"Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330\u20135. doi: 10.1056\/NEJM199505183322003 .","journal-title":"N Engl J Med"},{"issue":"4","key":"120_CR17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH03-09-0571","volume":"91","author":"AF Klenner","year":"2004","unstructured":"Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost. 2004;91(4):719\u201324. doi: 10.1267\/THRO04040719 .","journal-title":"Thromb Haemost"},{"key":"120_CR18","doi-asserted-by":"crossref","unstructured":"Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health. 2003;39(4):289\u201392. doi: 10.1046\/j.1440-1754.2003.00139.x .","DOI":"10.1046\/j.1440-1754.2003.00139.x"},{"issue":"1","key":"120_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thromres.2004.12.020","volume":"118","author":"L Risch","year":"2006","unstructured":"Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res. 2006;118(1):123\u201335. doi: 10.1016\/j.thromres.2004.12.020 .","journal-title":"Thromb Res"},{"issue":"11","key":"120_CR20","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/jth.12716","volume":"12","author":"SH O\u2019Brien","year":"2014","unstructured":"O\u2019Brien SH, Kulkarni R, Wallace A, Hamblin F, Burr S, Goldenberg NA. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. J Thromb Haemost. 2014;12(11):1822\u20135. doi: 10.1111\/jth.12716 .","journal-title":"J Thromb Haemost"},{"issue":"3","key":"120_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MPH.0b013e31816356f8","volume":"30","author":"CH Ommen van","year":"2008","unstructured":"van Ommen CH, van den Dool EJ, Peters M. Nadroparin therapy in pediatric patients with venous thromboembolic disease. J Pediatr Hematol Oncol. 2008;30(3):230\u20134. doi: 10.1097\/MPH.0b013e31816356f8 .","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"120_CR22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1592\/phco.27.9.1263","volume":"27","author":"JI Malowany","year":"2007","unstructured":"Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS. Enoxaparin use in the neonatal intensive care unit: experience over 8\u00a0years. Pharmacotherapy. 2007;27(9):1263\u201371. doi: 10.1592\/phco.27.9.1263 .","journal-title":"Pharmacotherapy"},{"key":"120_CR23","doi-asserted-by":"crossref","unstructured":"Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101(1):86\u201392. doi:09010086.","DOI":"10.1160\/TH08-03-0148"},{"issue":"6","key":"120_CR24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.thromres.2008.09.001","volume":"123","author":"ME Bauman","year":"2009","unstructured":"Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing. Thromb Res. 2009;123(6):845\u20137. doi: 10.1016\/j.thromres.2008.09.001 .","journal-title":"Thromb Res"},{"issue":"9","key":"120_CR25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2007.02624.x","volume":"5","author":"SH O\u2019Brien","year":"2007","unstructured":"O\u2019Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics\/pharmacokinetics study. J Thromb Haemost. 2007;5(9):1985\u20137. doi: 10.1111\/j.1538-7836.2007.02624.x .","journal-title":"J Thromb Haemost"},{"issue":"9","key":"120_CR26","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2010.03964.x","volume":"8","author":"MN Trame","year":"2010","unstructured":"Trame MN, Mitchell L, Krumpel A, Male C, Hempel G, Nowak-Gottl U. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost. 2010;8(9):1950\u20138. doi: 10.1111\/j.1538-7836.2010.03964.x .","journal-title":"J Thromb Haemost"},{"issue":"1","key":"120_CR27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.thromres.2009.08.003","volume":"125","author":"SM Duncan","year":"2010","unstructured":"Duncan SM, Massicotte MP, Ray L, Kuhle S, Bauman ME. Topical lidocaine and the effect on enoxaparin absorption in children: a pilot study. Thromb Res. 2010;125(1):e1\u20134. doi: 10.1016\/j.thromres.2009.08.003 .","journal-title":"Thromb Res"},{"issue":"6","key":"120_CR28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","volume":"57","author":"G Young","year":"2011","unstructured":"Young G, Yee DL, O\u2019Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18\u00a0years of age. Pediatr Blood Cancer. 2011;57(6):1049\u201354. doi: 10.1002\/pbc.23011 .","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"120_CR29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.thromres.2014.07.026","volume":"134","author":"RH Ko","year":"2014","unstructured":"Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res. 2014;134(3):643\u20137. doi: 10.1016\/j.thromres.2014.07.026 .","journal-title":"Thromb Res"},{"issue":"9","key":"120_CR30","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","volume":"94","author":"W Streif","year":"1999","unstructured":"Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94(9):3007\u201314.","journal-title":"Blood"},{"issue":"2 Suppl","key":"120_CR31","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S\u201384S. doi: 10.1378\/chest.11-2295 .","journal-title":"Chest"},{"issue":"6","key":"120_CR32","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/pbc.21731","volume":"51","author":"S Rayapudi","year":"2008","unstructured":"Rayapudi S, Torres A Jr, Deshpande GG, Ross MP, Wohrley JD, Young G, et al. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer. 2008;51(6):798\u2013801. doi: 10.1002\/pbc.21731 .","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"120_CR33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2007.02623.x","volume":"5","author":"G Young","year":"2007","unstructured":"Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6\u00a0months of age with thrombosis. J Thromb Haemost. 2007;5(8):1654\u20139. doi: 10.1111\/j.1538-7836.2007.02623.x .","journal-title":"J Thromb Haemost"},{"issue":"4","key":"120_CR34","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/PCC.0b013e31827200b6","volume":"14","author":"EL Nagle","year":"2013","unstructured":"Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14(4):e182\u20138. doi: 10.1097\/PCC.0b013e31827200b6 .","journal-title":"Pediatr Crit Care Med"},{"issue":"7","key":"120_CR35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pbc.22852","volume":"56","author":"G Young","year":"2011","unstructured":"Young G, Boshkov LK, Sullivan JE, Raffini LJ, Cox DS, Boyle DA, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011;56(7):1103\u20139. doi: 10.1002\/pbc.22852 .","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0120-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-015-0120-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0120-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T08:10:38Z","timestamp":1598775038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-015-0120-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1007\/s40272-015-0120-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]}}}